Navigation Links
MMS Holdings Leverages Medrio to Accelerate Clinical Trial Process for Study Sponsors Through New Contract
Date:5/8/2019

MMS Holdings – an award-winning, data-focused contract research organization (CRO) – has successfully leveraged the support services provided by Medrio, the leading provider of eClinical technology for small to mid-sized pharmaceutical companies, to execute a clinical trial sponsor agreement.

By collaborating to position high-quality CRO services with Medrio’s fast and easy-to-use eClinical products, MMS is actively demonstrating their ability to deliver a fast, flexible, and affordable solution for pharmaceutical sponsors of all sizes. The agreement exemplifies Medrio’s success in providing CROs with not only quality eClinical technology, but also robust support services that help them provide top-tier services to clinical trial sponsors and grow their business.

“Medrio does a lot to ease the process of doing business with our clients,” said Mindy Wolf, Senior Project Manager, MMS. “Their clear, straightforward pricing model makes it easy to get quotes and proposals out quickly. In clinical research, any delay translates to money wasted, so any efficiency in getting proposals issued and to decisions faster is helpful.”

Jim Bademian, Associate Director, Statistical Programming and Data Management at MMS, noted the value of Medrio’s integrated platform, which includes EDC as well as a suite of tablet applications: “We know that if we can offer a client one system provider to help meet all of their business needs, it will be a win for us, for Medrio, and for the client.”

MMS has been a Medrio user for over five years and has leveraged the platform in a multitude of studies. During this time, the company has benefitted significantly from various aspects of Medrio’s functionality, including the ability to:

  • Build study databases within two weeks
  • Quickly create reports for instant review
  • Easily access Medrio’s support team for any technical assistance they need

Their team has found particular success using Medrio in short-term studies. “Medrio is a good solution for sponsors who have very tight timelines,” says Bademian. “MMS can get the database up and running in a very short timeframe.”

“The success of MMS Holdings in facilitating this new sponsor relationship is a clear-cut example of the value of Medrio’s partnerships with our CRO customers,” noted Steve Geffon, Chief Commercial Officer at Medrio. “We’re thrilled to have supported their efforts and are excited to serve them in their upcoming research.”

To learn more about data management with MMS, visit us online.

About MMS Holdings
MMS is an award-winning, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named Most Outstanding Global CRO in the 2019 Biotechnology Awards. For more information, visit http://www.mmsholdings.com or follow MMS on LinkedIn.

About Medrio
Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company's cloud-based EDC, eSource, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please contact us at our website.

Read the full story at https://www.prweb.com/releases/mms_holdings_leverages_medrio_to_accelerate_clinical_trial_process_for_study_sponsors_through_new_contract/prweb16296113.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Zimmer Biomet Holdings to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
2. ID Global Solutions Corporation Announces the Acquisition of FIN Holdings Inc. Adding to IDGSs Advanced Biometric and Secure Credential Technologies
3. Quartesian LLC Executes Multi-Year Enterprise Agreement with Medrio, Securing Access to Innovative eClinical Functionality and Support Services
4. Visikol Launches OpenLiver™ 3D Cell Culture Models to Accelerate Drug Discovery
5. Smart Health Innovation Lab Partners with Redox to Help Innovative Healthcare Startups Accelerate Time to Integration
6. HireVue Expands C-Suite With Strategic Sales And Marketing Hires To Accelerate Growth Globally
7. Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine
8. Improved mouse model will accelerate research on potential Ebola vaccines, treatments
9. AERTOs accelerate the bioeconomy and the development of new lignin and algae products
10. Clemson scientists: Kudzu can release soil carbon, accelerate global warming
11. NSF and NIH collaborate to accelerate advance of biomedical innovations into the marketplace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 12, 2019 , ... With ... Abveris plans to leverage the Geneious Biologics platform as a premium hub for ... Officer at Abveris, says: “The Geneious team has done an excellent job accommodating ...
(Date:6/6/2019)... ... 05, 2019 , ... MedTech Breakthrough , an independent ... medical technology market, announced that it has selected Medacta International’s MySpine® MC platform ... the 2019 MedTech Breakthrough Awards program. , Medacta® is an ...
(Date:6/6/2019)... ... June 05, 2019 , ... Ziegler, a specialty investment bank, ... Bio-Medical Laboratories (PBM) on its recent acquisition by PathGroup. , Headquartered in ... to more than one dozen hospitals and surgery centers in the Dallas-Fort Worth ...
Breaking Biology News(10 mins):
(Date:7/9/2019)... ... July 08, 2019 , ... Today, at the ... National Corn Growers Association (NCGA) announced the winners of the Consider Corn ... product or process using field corn to produce biobased materials. , “Corn is a ...
(Date:6/18/2019)... ... June 18, 2019 , ... Personalized Stem Cells, Inc ... application to the FDA for use of a person’s own adipose-derived stem cells to ... osteoarthritis in the knee. This IND is the first of several planned clinical ...
(Date:6/11/2019)... ... June 11, 2019 , ... Mytonomy, ... a national leader in opioid treatment, announced today they are partnering to combat ... Mytonomy recently deployed its virtual care platform at the Mayo Clinic to drive ...
(Date:5/31/2019)... California (PRWEB) , ... May ... ... of our patent applications from the USPTO providing proprietary interest to our ... METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including ...
Breaking Biology Technology: